INTS1: The Integrator Complex Subunit 1 Drug Target and Biomarker

Target Name: INTS1

NCBI ID: G26173

INTS1

INTS1: The Integrator Complex Subunit 1 Drug Target and Biomarker

Introduction

The INTS1 gene, located on chromosome 16, encodes for the Integrator complex subunit 1 (ICSU1), a protein that plays a critical role in the intracellular signaling pathway known as the heterotrimeric G-protein-coupled receptor (HGPR) signaling pathway. INTS1 is a key regulator of various cellular processes, including cell adhesion, migration, and survival. The HGPR signaling pathway is a highly conserved protein-protein interaction network that plays a central role in the regulation of physiological processes such as growth, development, and reproduction.

INTS1 as a drug target

INTS1 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health and disease. The HGPR signaling pathway has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting INTS1 may provide new insights into the pathophysiology of these diseases and may lead to the development of new therapeutic approaches.

Targeting INTS1

Currently, although there are no drugs specifically targeting INTS1, studies have shown that inhibition of INTS1 can lead to therapeutic effects in various HGPR-mediated signaling pathways, such as the inhibition of cancer cell growth, neurodegenerative diseases, and developmental disorders. Therefore, targeting INTS1 may provide new insights into the pathophysiology of these diseases and may lead to the development of new therapeutic approaches.

Biomarker discovery

The INTS1 gene has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The expression of INTS1 has been observed in various disease tissues, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, the potential use of INTS1 as a biomarker in these diseases makes it an attractive target for future research.

Conclusion

INTS1 is a protein that plays a critical role in the HGPR signaling pathway and has been implicated in various diseases. Although there are currently no drugs specifically targeting INTS1, studies have shown that inhibition of INTS1 can lead to therapeutic effects in various HGPR-mediated signaling pathways. . Therefore, targeting INTS1 may provide new insights into the pathophysiology of these diseases and may lead to the development of new therapeutic approaches. Additionally, the potential use of INTS1 as a biomarker in various diseases makes it an attractive target for future research.

Protein Name: Integrator Complex Subunit 1

Functions: Component of the Integrator (INT) complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes (Probable). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the INT complex (PubMed:23904267)

The "INTS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets